Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
Price:
24.29 USD
6.02%
Updated:
May 15, 2024
Balance Sheet
Balance Sheet Decomposition
Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals Inc
| Current Assets | 541.7m |
| Cash & Short-Term Investments | 523.1m |
| Other Current Assets | 18.5m |
| Non-Current Assets | 413.5m |
| PP&E | 403.9m |
| Intangibles | 9.4m |
| Other Non-Current Assets | 210k |
| Current Liabilities | 65.2m |
| Accounts Payable | 8.5m |
| Accrued Liabilities | 56.1m |
| Other Current Liabilities | 573k |
| Non-Current Liabilities | 406.2m |
| Other Non-Current Liabilities | 406.2m |
Balance Sheet
Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals Inc
Currency: USD
| Sep-2014 | Sep-2015 | Sep-2016 | Sep-2017 | Sep-2018 | Sep-2019 | Sep-2020 | Sep-2021 | Sep-2022 | Sep-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
133
|
81
|
85
|
25
|
30
|
222
|
144
|
184
|
108
|
103
|
|
| Cash Equivalents |
133
|
81
|
85
|
25
|
30
|
222
|
144
|
184
|
108
|
103
|
|
| Short-Term Investments |
22
|
18
|
0
|
41
|
46
|
37
|
172
|
183
|
268
|
293
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
10
|
1
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
10
|
1
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
1
|
4
|
5
|
2
|
2
|
6
|
6
|
7
|
28
|
24
|
|
| Total Current Assets |
155
|
103
|
91
|
68
|
79
|
265
|
322
|
385
|
405
|
420
|
|
| PP&E Net |
4
|
5
|
15
|
16
|
14
|
23
|
47
|
66
|
169
|
336
|
|
| PP&E Gross |
4
|
5
|
15
|
16
|
14
|
23
|
47
|
66
|
169
|
336
|
|
| Accumulated Depreciation |
4
|
6
|
5
|
7
|
10
|
12
|
16
|
23
|
32
|
42
|
|
| Intangible Assets |
1
|
25
|
22
|
21
|
19
|
17
|
15
|
14
|
12
|
10
|
|
| Long-Term Investments |
23
|
0
|
0
|
0
|
0
|
44
|
138
|
246
|
106
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
183
N/A
|
132
-28%
|
128
-3%
|
104
-19%
|
112
+7%
|
350
+213%
|
523
+49%
|
710
+36%
|
692
-3%
|
766
+11%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
3
|
5
|
12
|
4
|
3
|
8
|
7
|
10
|
3
|
36
|
|
| Accrued Liabilities |
5
|
9
|
9
|
8
|
9
|
12
|
15
|
26
|
62
|
68
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
4
|
2
|
5
|
7
|
0
|
78
|
19
|
111
|
74
|
1
|
|
| Total Current Liabilities |
12
|
16
|
26
|
19
|
12
|
97
|
41
|
147
|
139
|
106
|
|
| Long-Term Debt |
1
|
1
|
3
|
2
|
2
|
0
|
0
|
0
|
0
|
0
|
|
| Minority Interest |
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
20
|
16
|
|
| Other Liabilities |
4
|
6
|
5
|
2
|
2
|
9
|
20
|
155
|
135
|
373
|
|
| Total Liabilities |
16
N/A
|
22
+36%
|
33
+48%
|
23
-31%
|
16
-30%
|
105
+566%
|
61
-42%
|
301
+396%
|
293
-3%
|
494
+68%
|
|
| Equity | |||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
225
|
317
|
398
|
433
|
487
|
419
|
504
|
645
|
821
|
1 026
|
|
| Additional Paid In Capital |
391
|
427
|
494
|
514
|
583
|
664
|
965
|
1 053
|
1 219
|
1 300
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
|
| Total Equity |
167
N/A
|
110
-34%
|
96
-13%
|
81
-15%
|
96
+18%
|
245
+155%
|
462
+89%
|
409
-11%
|
399
-3%
|
271
-32%
|
|
| Total Liabilities & Equity |
183
N/A
|
132
-28%
|
128
-3%
|
104
-19%
|
112
+7%
|
350
+213%
|
523
+49%
|
710
+36%
|
692
-3%
|
766
+11%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
55
|
60
|
70
|
75
|
89
|
96
|
102
|
104
|
106
|
107
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
